Abstract
Vaccine adjuvants intensify immune responses against co-inoculated antigens and depend on biophysical properties to be efficient. There is great pharmaceutical interest in developing new adjuvants that are able to activate CD1d-restricted T cells, because they recognize lipid antigens and influence immune responses related to several pathogens, autoimmune diseases and cancer. Due to its p…